Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGSWW) EBITDA (2020 - 2025)

GeneDx Holdings has reported EBITDA over the past 6 years, most recently at -$17.7 million for Q4 2025.

  • Quarterly results put EBITDA at -$17.7 million for Q4 2025, down 431.44% from a year ago — trailing twelve months through Dec 2025 was -$20.9 million (up 59.69% YoY), and the annual figure for FY2025 was -$20.9 million, up 59.69%.
  • EBITDA for Q4 2025 was -$17.7 million at GeneDx Holdings, down from -$7.4 million in the prior quarter.
  • Over the last five years, EBITDA for WGSWW hit a ceiling of $32.7 million in Q3 2021 and a floor of -$308.8 million in Q4 2022.
  • Median EBITDA over the past 5 years was -$34.6 million (2021), compared with a mean of -$52.1 million.
  • Biggest five-year swings in EBITDA: skyrocketed 157.81% in 2021 and later tumbled 668.35% in 2022.
  • GeneDx Holdings' EBITDA stood at -$40.2 million in 2021, then tumbled by 668.35% to -$308.8 million in 2022, then soared by 91.79% to -$25.3 million in 2023, then soared by 121.11% to $5.4 million in 2024, then crashed by 431.44% to -$17.7 million in 2025.
  • The last three reported values for EBITDA were -$17.7 million (Q4 2025), -$7.4 million (Q3 2025), and $10.7 million (Q2 2025) per Business Quant data.